More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines...
Amgenhelped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today.Amgenis advancing a broad
References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis" and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and ot...
Get Started
Hi. Thanks for taking the question. Two-part on MariTide as well. Just wondering if you can confirm if the data disclosure will be a press release or it will be at a conference. I think the Phase 1 data were presented at the insulin resistance conference in December. So, just wondering...
Amgen (NASDAQ: AMGN) today announced that the FDA has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory...
(August 5, 2019) “Today, Momenta announced the Company will cease active development of M923 at this time, due to changes in the market opportunity associated with Humira patent litigation settlements,” according to a company press release. CONTINUE READING FDA Approves Biosimilars for Adalimumab...
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Amgen, its collaboration partner for MP0310 (AMG 506), has informed the Company of their dec...
THOUSAND OAKS, Calif., Jan. 28, 2014/PRNewswire/--Amgen (NASDAQ: AMGN) today announced that the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaLAntibody Inhibition Combined with Statin ThErapy-2) trial evaluatingPR NewswireNasdaq Com...
Amgen Media Press Release (2006). Anonymous, UCB on track. UCB News (2007). Anonymous, UCB on track. UCB News (2007). Arnett et al., Effect of pH on bone resorption by rat osteoclasts in vitro. Endocrinol., 119(1):119-124 (1986). Attana Application Example, cited in ...